A real-world study to compare cardiovascular risk factors associated with Dipeptidyl Peptidase-4 Inhibitors Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin or Gemigliptin

Trial Profile

A real-world study to compare cardiovascular risk factors associated with Dipeptidyl Peptidase-4 Inhibitors Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin or Gemigliptin

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Gemigliptin (Primary) ; Linagliptin (Primary) ; Saxagliptin (Primary) ; Sitagliptin (Primary) ; Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2017 New trial record
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top